8 cardiovascular biologic innovations hitting the 2026 clinical mainstream The start of 2026 is being marked by a profound expansion of biologics into the realm of cardiovascular health, specifically targeting the inflammatory components of atherosclerosis and heart failure. High-profile studies released in early 2026 demonstrate that specific monoclonal antibodies can shrink arterial plaques, a goal that was once considered unattainable through medication alone. As...
จองคิวบริการ
NR tours
Youplay
NR shop
NR jobs
facebook th
